Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
News|Articles|May 4, 2023
Daily Dose: Sex Difference in Outcomes of AMI in Young Adults
Author(s)Sydney Jennings
Advertisement
Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.
On May 3, 2023, we reported on a study published in the Journal of the American College of Cardiology that aimed to determine sex differences in causes and timing of 1-year outcomes after acute myocardial infarction (AMI) in persons aged 18-55 years.
The study
Investigators analyzed data from 2979 participants (2007 women, 972 men) from the VIRGO study, which enrolled young adults with AMI across 103 US hospitals. Researchers assessed sex differences in all-cause and cause-specific hospitalizations by calculating incidence rates ([IRs] per 1000 person-years) and IR ratios (IRR).
The findings
The leading causes of hospitalization were coronary related for both sexes but incidence rates for women were higher than for men (IR 171.8, 95% CI 153.6-192.2 among women vs 117.8, 95% CI 97.3-142.6 among men), followed by noncardiac hospitalization (IR 145.8, 95% CI 129.2-164.5 among women vs 69.6, 95% CI 54.5-88.9 among men).
Investigators also observed sex-based differences for coronary-related hospitalizations (subdistribution HR [SHR] 1.33, 95% CI 1.04-1.70; P=.02) and noncardiac hospitalizations (SHR 1.51, 95% CI 1.13-2.07; P=.01).
Note from authors
"Young women with AMI have persistently worse outcomes compared with men immediately and 1 year after discharge. Coronary-related hospitalizations were the most common cause of hospitalizations, but noncardiac hospitalizations showed the greatest sex disparity among young patients after AMI. Further studies to better understand the underlying mechanisms of noncardiac hospitalizations are warranted."
Click here for more details.
Advertisement
Related to this article
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
Cheryl Cox Kinney, MD, explains when night sweats warrant further evaluation, including red flags, persistent symptoms, and potential nonmenopausal causes.
TMS 2026: Menopause was coded in just 7.8% of midlife outpatient visits. Arina Chesnokova, MD, MPH, discusses diagnosis gaps, prescribing risks, and solutions for primary care.
Investigational CagriSema produced 23.1% to 26.7% weight loss across menopause stages at 68 weeks, with improvements in cardiometabolic risk factors.
TMS 2026: Nearly 67% of US women receiving elinzanetant achieved at least a 50% reduction in menopausal VMS frequency by week 12 in pooled phase 3 trial data.
TMS 2026: Only 21.7% of women initiated menopause hormone therapy, with significant racial disparities and low treatment persistence, a new study finds.
TMS 2026: OB/GYN visits had nearly 4-fold higher odds of menopause coding than family medicine visits, with disparities by race and insurance, a study found.
Advertisement
Advertisement